Local Anesthesia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for local anesthesia. 186 active patents protecting 4 drugs from 4+ originators. First major cliff: 2026. Daily refresh.

4
Approved drugs
186
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Local Anesthesia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Innocoll 108 patents Johnson & Johnson (Janssen Pharmaceutica) 68 patents Generic (originally Roche) 6 patents Fresenius Kabi 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating local anesthesia. Each bar = one year. Y-axis scaled to peak year (54 patents).

1
26
54
27
4
28
1
29
14
30
20
34
42
35
4
36
2
38
30
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Bupivacaine Hydrochloride And Epinephrine
BUPIVACAINE
 Innocoll 108 64 — 2034-03-13
Duragesic
fentanyl
 Johnson & Johnson (Janssen Pharmaceutica) 68 51 — 2027-01-25
Versed
midazolam
 Generic (originally Roche) 6 61 — 2028-01-18
Lignospan Forte
Lidocaine Hydrochloride
 Fresenius Kabi 4 71 — 2026-07-24

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759401 Lignospan Forte method of use 85 2026-07-24
9687495 Versed method of use 75 2028-01-18
9289432 Versed method of use 75 2028-01-18
8217033 Versed method of use 75 2028-01-18
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
12144890 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22
12144890 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
10966990 Versed formulation 42 2038-06-20
10966990 Versed formulation 42 2038-06-20
10980886 Bupivacaine Hydrochloride And Epinephrine formulation 42 2035-04-20

Related